Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Falling Fed rates and favorable policies make XLV a strong healthcare ETF pick. Read here for an analysis of its growth ...

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

The moves, to lower the cost of a drug prescribed to women going through IVF and boost employer coverage, follow Trump’s campaign promise to make fertility care more accessible.

The Trump administration has struck a deal with EMD Serono to lower drug prices — part of a larger push from the ...

According to a Securities and Exchange Commission (SEC) filing dated October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV ...

QSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter. After the transaction ...

After weeks of confusion, approval by CDC and its acting director mean most Nebraskans can get COVID-19 vaccines after consulting with a health care provider, including pharmacists.

OPKO Health, Inc. is refocusing on drug development, selling BioReference Lab assets to strengthen its balance sheet. Learn ...